Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sargramostim and/or Peptide Vaccine in Resected Melanoma
NCT01989572Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2000
- Primary completion
- Oct 2012
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sargramostim and tyrosinase peptide in melanoma (6 arms), sponsored by National Cancer Institute. Primary endpoints: Overall Survival up to 15 years and Recurrence Free Survival up to 15 years. Started Feb 2000; status: completed.
02
Drugs
sargramostimtyrosinase peptide
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01989572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01989572.